VGX-3100 + Imiquimod 5% Cream
Phase 2CompletedDevelopment Stage
Vulvar High Grade Squamous Intraepithelial Lesion (HSIL)
Vulvar High Grade Squamous Intraepithelial Lesion (HSIL), Vulvar Dysplasia, Vulvar Intraepithelial Neoplasia (VIN), VIN2, VIN3, Pre-cancerous Lesions of the Vulva, Human Papillomavirus (HPV)
Aug 31, 2017 → Dec 18, 2020
About VGX-3100 + Imiquimod 5% Cream
VGX-3100 + Imiquimod 5% Cream is a phase 2 stage product being developed by Inovio Pharmaceuticals for Vulvar High Grade Squamous Intraepithelial Lesion (HSIL). The current trial status is completed. This product is registered under clinical trial identifier NCT03180684. Target conditions include Vulvar High Grade Squamous Intraepithelial Lesion (HSIL), Vulvar Dysplasia, Vulvar Intraepithelial Neoplasia (VIN).
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03180684 | Phase 2 | Completed |
Competing Products
7 competing products in Vulvar High Grade Squamous Intraepithelial Lesion (HSIL)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Tacrolimus cream + Clobetasol cream | Astellas Pharma | Phase 2 | 52 |
| Estradiol | Sun Pharmaceutical | Phase 3 | 77 |
| Estradiol Vaginal Tablets 10 mcg (Glenmark) + Vagifem® (Estradiol Vaginal Tablets) 10 mcg (Novo Nordisk) + Placebo of Estradiol Vaginal Tablets 10 mcg (Glenmark) | Glenmark Pharmaceuticals | Phase 3 | 77 |
| Cisplatin + Pembrolizumab | Merck | Phase 2 | 52 |
| Cardunolizumab | Innovent Biologics | Phase 2 | 51 |
| AK104 + AK104+ Paclitaxel+Cisplatin or Carboplatin | Akeso | Phase 2 | 51 |
| AVA6103 | Avacta Group | Phase 1 | 25 |